Sutro strengthens its immune-oncology pipeline with two new ADCs
In June, Sutro received a $140m payment from Blackstone Life Sciences as part of the Vaxcyte product licensing agreement.
11 August 2023
11 August 2023
In June, Sutro received a $140m payment from Blackstone Life Sciences as part of the Vaxcyte product licensing agreement.
Vistagen is preparing for two Phase III trials with fasedienol in 2024 after a missed primary endpoint last year.
Amid unceasing demand for its blockbuster drug Wegovy, Novo Nordisk is adding a CB1 blocker to its weight loss drug pipeline.
Babylon, Galera and more are cutting staff, serving as a reminder that failure is easy in the medical world.
Three months after the vaccination, the study will assess immune responses in the vulnerable patients.
Top-line results from the trial are expected in the second half of next year.
The normalisation of ALP at 52 weeks is the primary outcome measure of the study.
Determining the maximum tolerated dose and/or the recommended doses for trial extensions is the primary objective of the study.
We will be launching our new event Clinical Trials In Rare Diseases Conference 2023 at Princeton Marriott at Forrestal, New Jersey, USA on 13th-14th September! Bringing together clinical operations professionals from across multiple therapeutic areas to discuss common obstacles and solutions and much more. With over 40 solution providers this will be a perfect platform to reconnect with current business partners, meet new vendors and discover which new technologies are being employed to improve your Rare Disease clinical trials.
The COVID-19 pandemic pushed the healthcare industry to rapid digitalization. Increased use of telehealth, telepresence systems, remote diagnostics, predictive AI, and wearable technology is changing how healthcare is delivered and improving patient outcomes. Emerging technologies such as AR and VR are becoming increasingly routine for professional training, surgical assistance, and treatment of psychological and neurological disorders. In the pharma and medical devices industries, AR, VR, and AI are rapidly accelerating drug discovery and manufacturing and generating supply chain efficiencies. New digital opportunities will look to build upon disruptive technologies. However, affordability is a limiting factor to widespread adoption. Per GlobalData estimates, the metaverse market is expected to grow at a CAGR of more than 33% between 2023 and 2030. Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns. Evidence of proven use cases and participation by a critical mass of users are imperative to drive a shift in metaverse investment.
Give your business an edge with our leading industry insights.